Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts

source extracted confidence: high 2026-04-09
#adult #clinical-trials-as-topic #colestipol #coronary-artery-bypass #coronary-artery-disease

Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts

Blankenhorn et al., 1987 | JAMA | Rct

Citation

Blankenhorn D H, Nessim S A, ... Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987-Jun-19;257(23):3233-40

Abstract

The Cholesterol-Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-controlled, angiographic trial testing combined colestipol hydrochloride and niacin therapy in 162 nonsmoking men aged 40 to 59 years with previous coronary bypass surgery. During two years of treatment there was a 26% reduction in total plasma cholesterol, a 43% reduction in low-density lipoprotein cholesterol, plus a simultaneous 37% elevation of high-density lipoprotein cholesterol. This resulted in a significant reduction in the average number of lesions per subject that progressed (P less than .03) and the percentage of subjects with new atheroma formation (P less than .03) in native coronary arteries. Also, the percentage of subjects with new lesions (P less than .04) or any adverse change in bypass grafts (P less than .03) was significantly reduced. Deterioration in overall coronary status was significantly less in drug-treated subjects than placebo-treated subjects (P less than .001). Atherosclerosis regression, as indicated by perceptible improvement in overall coronary status, occurred in 16.2% of colestipol-niacin treated vs 2.4% placebo treated (P = .002).

Key Findings

Atherosclerosis regression, as indicated by perceptible improvement in overall coronary status, occurred in 16.2% of colestipol-niacin treated vs 2.4% placebo treated (P = .002).

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population new atheroma formation
Sample Size See abstract
Age Range 40 to 59 years
Condition See abstract

MeSH Terms

  • Adult
  • Clinical Trials as Topic
  • Colestipol
  • Coronary Artery Bypass
  • Coronary Artery Disease
  • Drug Therapy, Combination
  • Graft Occlusion, Vascular
  • Humans
  • Lipids
  • Male
  • Middle Aged
  • Niacin
  • Polyamines
  • Radiography
  • Random Allocation

Evidence Classification

  • Level: Rct
  • Publication Types: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
  • Vertical: niacin-atherosclerosis

Provenance

  • PMID: 3295315
  • DOI: (not available)
  • PMCID: Not in PMC
  • Verified: 2026-04-09 via PubMed E-utilities API

Source extracted via PubMed E-utilities API on 2026-04-09